Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News

News :

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors 
The feature you requested does not exist. However, we suggest the following feature:

Technical Perspectives on Biotech Stocks -- Aimmune Therapeutics, Atara Biotherapeutics, AveXis, and Axsome Therapeutics

share with twitter share with LinkedIn share with facebook
share via e-mail
03/19/2018 | 11:41am CET

NEW YORK, March 19, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on AIMT, ATRA, AVXS, and AXSM which can be accessed for free by signing up to www.wallstequities.com/registration. For today, WallStEquities.com covers the Biotech industry, which consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. Stocks under evaluation this morning are: Aimmune Therapeutics Inc. (NASDAQ: AIMT), Atara Biotherapeutics Inc. (NASDAQ: ATRA), AveXis Inc. (NASDAQ: AVXS), and Axsome Therapeutics Inc. (NASDAQ: AXSM). All you have to do is sign up today for this free limited time offer by clicking the link below.


Aimmune Therapeutics

Brisbane, California headquartered Aimmune Therapeutics Inc.'s stock finished last Friday's session 2.01% lower at $31.65. A total volume of 2.02 million shares was traded, which was above their three months average volume of 922,370 shares. The Company's shares have advanced 43.47% over the past year. The stock is trading above its 200-day moving average by 11.93%. Additionally, shares of Aimmune Therapeutics, which develops and commercializes product candidates for the treatment of peanut and other food allergies, have a Relative Strength Index (RSI) of 39.84.  

On March 07th, 2018, Aimmune Therapeutics announced that CEO Stephen Dilly, M.B.B.S., Ph.D. will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27th, 2018, at 4:30 p.m. ET in New York, NY. A live webcast of the presentation will be accessible on the Events page under the Investor Relations section of the Company's website. Get the full research report on AIMT for free by clicking below at:


Atara Biotherapeutics

On Friday, shares in Brisbane, California headquartered Atara Biotherapeutics Inc. ended the session flat at $41.90. The stock recorded a trading volume of 2.97 million shares, which was higher than its three months average volume of 1.07 million shares. The Company's shares have skyrocketed 185.03% in the previous three months and 124.66% over the past year. The stock is trading 15.78% above its 50-day moving average and 108.36% above its 200-day moving average. Moreover, shares of Atara Biotherapeutics, which focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology, have an RSI of 52.93.  

On February 21st, 2018, Atara Biotherapeutics (ATRA) announced that John McGrath, Executive Vice President and CFO, intends to retire from the Company as of April 27th, 2018. ATRA is initiating a search for its next CFO, who will play an instrumental leadership role in its continued evolution into a global commercial T‑cell immunotherapy company.

On March 16th, 2018, research firm Guggenheim initiated a 'Neutral' rating on the Company's stock. Access the free research report on ATRA now by signing up at:



Bannockburn, Illinois headquartered AveXis Inc.'s shares dropped 2.50%, closing the session at $128.07. A total volume of 625,746 shares was traded, which was above their three months average volume of 518,930 shares. The stock has gained 10.79% in the last month, 30.23% over the previous three months, and 75.97% over the past year. The Company's shares are trading 8.72% and 29.79% above their 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases, have an RSI of 55.71.  

On February 27th, 2018, AveXis reported its results for the quarter and year ended December 31st, 2017. For Q4 2017, R&D expenses were $51.4 million, G&A expenses were $31.1 million, and net loss was $(81.7) million. For the full year, R&D expenses were $150.4 million, G&A expenses were $70.0 million, and net loss was $(218.1) million. Are you already registered with Wall St. Equities? Do so now for free, and get the report on AVXS at:


Axsome Therapeutics

Last Friday, shares in New York-based Axsome Therapeutics Inc. recorded a trading volume of 324,408 shares. The stock ended the session 1.89% higher at $2.70. The Company's shares have advanced 3.85% in the past month. The stock is trading below its 50-day moving average by 10.80%. Furthermore, shares of Axsome Therapeutics have an RSI of 48.13.  

On March 07th, 2018, Axsome Therapeutics reported its results for Q4 and year ended December 31st, 2017. For Q4 2017, R&D expenses were $4.5 million, G&A expenses were $2.0 million, and net loss was $(7.4) million. For the full year 2017, R&D expenses were $20.0 million, G&A expenses were $7.2 million, and net loss was $(28.9) million. Aspiring Member, please take a moment to register below for your free research report on AXSM at:



Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: +21-32-044-483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----aimmune-therapeutics-atara-biotherapeutics-avexis-and-axsome-therapeutics-300615763.html

SOURCE Wall St. Equities

© PRNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news
11:40aFollow our latest news on social media!
11:39aMANCHESTER UNITED : Andreas Christensen sought John Terry advice after dip in form at Chelsea
11:38aRITTER PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
11:37aUK home-sellers raise prices by most since 2007 - Rightmove
11:37aELECTRONICS FOR IMAGING INC - 10-K/A - : Management's Discussion and Analysis of Financial Condition and Results of Operations
11:36aGOLDMAN SACHS : Co-head of Goldman Sachs Germany to be become deputy German finance minister
11:36aLVMH MOËT HENNESSY VUITTON : Dior Homme Artistic Director to Step Down
11:36aThis Morning's Technical Outlook on Banking Stocks -- Comerica, First Republic Bank, Banco Santander-Chile, and Bank of America
11:35aRitter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
11:34aORASCOM CONSTRUCTION : joint venture awarded $180m for Fujairah Airport Expansion
Latest news